Alteration in sexually dimorphic testosterone biotransformation profiles as a biomarker of chemically induced androgen disruption in mice.
Assessment of the impact of environmental chemicals on androgen homeostasis in rodent models is confounded by high intraindividual and interindividual variability in circulating testosterone levels. Our goal was to evaluate changes in testosterone biotransformation processes as a measure of androgen homeostasis and as a biomarker of exposure to androgen-disrupting chemicals. Sex-specific differences in hepatic testosterone biotransformation enzyme activities were identified in CD-1 mice. Gonadectomy followed by replacement of individual steroid hormones identified specific sex differences in biotransformation profiles that were due to the inductive or suppressive effects of testosterone. Notably, significant androgen-dependent differences in testosterone 6[alpha]- and 15[alpha]-hydroxylase activities were demonstrated, and the ratio of 6[alpha]- and 15[alpha]-hydroxylase activities proved to be an excellent indicator of the androgen status within the animal. The male or "masculinized" testosterone 6[alpha]/15[alpha]-hydroxylase ratio was significantly less than the female or "feminized" ratio. Male mice were exposed to both an antiandrogen, vinclozolin, and to a compound that modulates serum androgen levels, indole-3-carbinol, to test the utility of this ratio as a biomarker of androgen disruption. Treatment with the antiandrogen vinclozolin significantly increased the 6[alpha]/15[alpha]-hydroxylase ratio. Indole-3-carbinol treatment resulted in a dose-dependent, but highly variable, decrease in serum testosterone levels. The 6[alpha]/15[alpha]-hydroxylase ratio increased as serum testosterone levels decreased in these animals. However, the increase in the ratio was much less variable and more sensitive than serum testosterone levels. These investigations demonstrate that the 6[alpha]/15[alpha]-hydroxylase ratio is a powerful measure of androgen modulation and a sensitive indicator of exposure to androgen-disrupting chemicals in CD-1 mice.
Wilson
V S
VS
Department of Toxicology, North Carolina State University, Raleigh, NC 27695, USA.
McLachlan
J B
JB
Falls
J G
JG
LeBlanc
G A
GA
D000728:Androgens / Q000378:metabolism*; D000818:Animals; D015415:Biomarkers; D001711:Biotransformation; D004958:Estradiol / Q000627:therapeutic use; D005260:Female; D006706:Homeostasis / Q000187:drug effects; D020249:Hormone Replacement Therapy; D008297:Male; D051379:Mice; D009919:Orchiectomy; D010052:Ovariectomy; D010053:Ovary / Q000187:drug effects; D011374:Progesterone / Q000627:therapeutic use; D015203:Reproducibility of Results; D012727:Sex Characteristics; D013737:Testis / Q000187:drug effects; D013739:Testosterone / Q000493:pharmacokinetics*
D000728:Androgens; D015415:Biomarkers; D013739:Testosterone; D011374:Progesterone; D004958:Estradiol